The gut microbiome, or the collection of bacteria in our gut, has been shown to play a significant role in developing and progressing diseases involving inflammation, including Alzheimer’s disease (AD). Studies have found that AD patients have a different gut microbiome composition compared to healthy individuals, and altering the gut microbiome in mouse models has been linked to changes in AD-related pathology. There is a growing interest in understanding how the gut microbiome can affect AD through various pathways, such as microbial metabolites. Using new technologies and better human-relevant models will help researchers better understand how the gut microbiome influences AD and whether therapies targeting the gut microbiome can be personalized to each patient.  

https://doi.org/10.1186/s13024-023-00595-7


Leave a comment